Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients
- Resource Type
- Authors
- Xiaolei Liu; Shuzhen Liu; Aiying Qin; Haipeng Ren; Kongyuan Zhang; Baohong Yang; Xiangpo Pan; Guohua Yu
- Source
- Oncology Research
- Subject
- Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Pathology
Lung Neoplasms
medicine.drug_class
Article
Disease-Free Survival
Tyrosine-kinase inhibitor
Erlotinib Hydrochloride
03 medical and health sciences
Prognostic marker
0302 clinical medicine
Gefitinib
Circulating tumor cell
Growth factor receptor
Carcinoma, Non-Small-Cell Lung
Internal medicine
Humans
Medicine
Lung cancer
Protein Kinase Inhibitors
neoplasms
Circulating tumor cells (CTCs)
Aged
Neoplasm Staging
Univariate analysis
business.industry
General Medicine
Middle Aged
Neoplastic Cells, Circulating
Prognosis
medicine.disease
ErbB Receptors
030104 developmental biology
030220 oncology & carcinogenesis
Quinazolines
Female
Erlotinib
EGFR-mutant non-small cell lung cancer (NSCLC)
business
Tyrosine kinase
medicine.drug
- Language
- ISSN
- 0965-0407
Epithelial growth factor receptor (EGFR) mutations are present in 10%‐26% of non-small cell lung cancer (NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possible role in providing prognostic information. Enrolled patients received erlotinib (150 mg) or gefitinib (250 mg) orally once daily as the first-line treatment. Serial blood samples were taken at baseline (CTC-d0) and on day 28 (CTC-d28) following the initiation of erlotinib/gefitinib for detection of CTCs using the CellSearch system. CTCs ≥2 were found in 47/107 (44%) and CTCs ≥5 in 17/107 (15%). The CTC measurements were dichotomized as favorable (p = 0.009). Patients in the favorable group on day 28 exhibited significantly longer PFS compared with patients in the unfavorable group (11.6 vs. 6.3 months; p